ALK and non-small cell lung carcinoma: Immunotherapy alone is ineffective in NSCLC with mutation of EGFR or rearrangement of ALK and ROS1 [9, 10], but the IMpower150 trial demonstrated that combining the anti-PD-L1 atezolizumab with the anti-vascular endothelial growth factor (anti-VEGF) bevacizumab and chemotherapy improved PFS (hazard ratio [HR] 0.59) among patients with EGFR mutations [11].